very interesting new idea brought to my attention by RHPS today.

http://www.phosphagenics.com/ is the company website and

www.cohenresearch.com has an interesting report on them

with new phosphorylation techniques (inserting a phosphate group into the chemical structure to make it much more readily absorbed into the body), they aim to deliver more effectively previously hard to transmit drugs to the body - Vitamin E (already successfully launched in US), morphine (much smaller amounts needed, so fewer side effects), and others

talks with FDA started on basis of an enhanced delivery rather than enhanced drug action - much simpler process

recently gained Aus government grant of Aus$1.7 to fund Phase I and Pre-Phase II human trials of transdermal morphine delivery

a Material Evaluation Agreement signed with major US pharma to apply PSG's technology to its patented systems

forward PE of 0.54 (yes I did get the decimal point in the right place!)

shares up from about 7p to 12p over last 3 months

listed on Ausraillian Stock Market and London AIM

must be interesting to watch at least. DYOR then do it again to make sure I'm not dreaming.

check it out and ket me know what you think

cheers
SD

That's what I've got!! metabolic syndrome-where can I buy some??? lol

hmmm interesting share stockdog... wonder if these will drift some more before the perfect entry point (reading the research note, they do seem to have alot of potential)

2006-05-08 07:01:34
Phosphagenics Limited - Research Update
Phosphagenics initiates Phase 2a clinical trial of its transdermal morphine
cream

Melbourne, VIC, Australia, 8 May 2006

Phosphagenics Limited ("Phosphagenics"), the Australian Stock Exchange (ASX:
POH) and the London Stock Exchange's Alternative Investment Market (AIM:PSG)
listed pharmaceutical and nutraceutical company, today announces commencement
of a Phase 2a clinical trial of its transdermal morphine cream, TPM-01/
Morphine. The Phase 2a trial, investigating the efficacy, absorption, and
metabolism of morphine administered using Phosphagenics' novel transdermal
carrier TPM-01, will be conducted at the Royal Adelaide Hospital, South
Australia. Preliminary results are expected during the third quarter of 2006.

In the trials, doses of morphine will be examined in 48 healthy male volunteers
aged between 18 and 49 years. Volunteers will be randomly assigned into a dose
group and either receive active treatment or placebo treatment in a double
blinded manner. The efficacy of Phosphagenics transdermal morphine in producing
the well recognised effects of morphine in humans, such as changes in pupil
size and decreased response to painful stimuli, will be measured.

Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics,
said: "The initiation of phase 2a clinical trials of morphine with our
proprietary transdermal delivery technology is a significant milestone in the
development or our pain management product. It will also provide further
clinical proof of the efficacy of Phosphagenics' transdermal delivery
technology."

About Phosphagenics' Transdermal Morphine

Phosphagenics' transdermal morphine (TPM-01/Morphine) is a non-invasive,
patient-friendly gel or cream that delivers morphine through the skin into the
bloodstream. Previous clinical trials of TPM-01/Morphine have achieved 48 hours
of therapeutic morphine blood levels from a single dose, which compares
favourably to the longest acting morphine products available which provide only
up to 24 hours of therapeutic blood levels per dose.

Phosphagenics expects that a transdermal product capable of providing
therapeutic blood levels of morphine for 48 hours or longer would fill an unmet
clinical need for chronic pain patients (by minimising the occurrence of
"breakthrough pain") and provide cost-effective treatment solutions for hospice
patients, especially those unable to swallow oral preparations of morphine.
There is currently no commercially available transdermal morphine product.

ENDS

Notes to Editors

About Phosphagenics' Transdermal Carrier Technology

Phosphagenics patented transdermal technology is a carrier that utilises
existing natural transport mechanisms to "carry" drugs across the skin without
disrupting the surface of the skin. In contrast, alternative transdermal
technologies either: rely on passive diffusion across skin membranes improving
drug penetration with solvents, enhancers or lasers that modify the properties
of the outermost layers of the skin; or, use electrical or thermal technologies
to "push" drugs through the skin.

Both formulations of the carrier (TPM-01 and TPM-02) have anti-inflammatory and
anti-erythema properties which minimise skin irritation, can provide sustained
transdermal delivery of drugs and can deliver a range of drugs through the
skin. TPM-01 delivers small molecule drugs (e.g. morphine, fentanyl, oxycodone,
atropine, estradiol, testosterone) and TPM-02 delivers both small and large
molecule drugs (e.g. insulin, PTH, proteins).

About Phosphagenics Limited

Phosphagenics is a pharmaceutical and nutraceutical company with a diversified
portfolio of technologies encompassing drug delivery, drug enhancement, and
active ingredients for the nutraceutical industry (dietary supplements,
functional foods and personal care products).

Phosphagenics is based in Melbourne, Australia. Its shares are listed on the
Australian Stock Exchange (POH) and the London Stock Exchange's Alternative
Investment Market (PSG). An American Depository Receipts-Level 1 facility has
been established in the US with the Bank of New York (PPGNY) for the trading of
the Company's shares in the US `Over the Counter' market. Further information
regarding Phosphagenics can be found at www.phosphagenics.com.

For further information please contact:

Phosphagenics Limited:

Dr Esra Ogru, Executive Director Research & Development

Ph: +61 3 9605 5900 or 0402 080 846

Northbank Communications

Rowan Minnion

Ph: +44 (0)20 7886 8150

r.minnion@northbankcommunications.com




END

.

Mention in shares mag today. Not read it, got it from todays news paper round up.

Plays of the Week: Buy Manganese Bronze at 222.5p - Financial Objects at 46p

Updates: Buy Ascribe and Titan Europe

Something in the Pipeline: Protherics - Skyepharma - Alizyme - Plethora Solutions - Ark Therapeutics - Phosphagenics - Ardana

.

hang on, forest, I'll just get my micro-dot reader!

sd

Thats what my mrs says!! LOL not.

over 7 million traded in oz last night, up 6.5%. Take a look at chart from start of 2004 just b4 the large spike, very similar to the one we have now. (The four steps)

Reason for dot, phone rang and had to go out. easy to find psg when i got back.

Any further developments since Shares' mention to cause the welcome lift in price last week, on reasonable volume too?

Next stop Jan's 15.5p highs?

sd

23 August 2006

Phosphagenics Limited

On 22 August 2006, the Australian Stock Exchange ("ASX") published a response
by the Company to an ASX query regarding a change in the Company's share price.
Both the published query and response are set out below:

Query:

21 August 2006

Mourice Garbutt

Company Secretary

Phosphagenics Limited

By Email only

Dear Mourice

Phosphagenics Limited (the "Company")

RE: PRICE QUERY

We have noted a change in the price of the Company's securities from a low of
$0.29 on 7 August 2006 to $0.365 at the time of writing. We have also noted an
increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of
the following questions.

1. Is the Companyaware of any information concerning it that has not been
announced which, if known, could be an explanation for recent trading in
the securities of the Company?

2. If the answer to question 1 is yes, can an announcement be made
immediately? If not, why not and when is it expected that an announcement
will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be
made immediately, you need to contact us to discuss this and you need to
consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating
loss before abnormal items and income tax so that the figure for the half year
ended 30 June 2006 would vary materially from the previous corresponding
period. If so, please provide details as to the extent of the likely variation.

4. Is there any reason to think that the Company may record any material
abnormal or extraordinary items for the half year ended 30 June 2006? If so,
please provide details.

5. Is there any other explanation that the Company may have for the price
change and increase in volume in the securities of the Company?

6. Please confirm that the Company is in compliance with the listing rules and,
in particular, listing rule 3.1.

Your response should be sent to me by return e-mail or by facsimile on
facsimile number (03) 9614 0303. It should not be sent to the Company
Announcements Office.

Unless the information is required immediately under listing rule 3.1, a
response is requested as soon as possible and, in any event, not later than
half an hour before the start of trading (ie before 9.30 a.m. ) on Tuesday, 22
August 2006).

Under listing rule 18.7A, a copy of this query and your response will be
released to the market, so your response should be in a suitable form and
separately address each of the questions asked. If you have any queries or
concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information
concerning it that a reasonable person would expect to have a material effect
on the price or value of the entity's securities. The exceptions to this
requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance
Note 8 - Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given
to ASX under listing rule 3.1 your obligation is to disclose the information
immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily
satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to
question 1 is yes and an announcement cannot be made immediately, you should
consider a request for a trading halt in the Company's securities. As set out
in listing rule 17.1 and Guidance Note 16 - Trading Halts we may grant a
trading halt at your request. We may require the request to be in writing. We
are not required to act on your request. You must tell us each of the
following.

* The reasons for the trading halt.

* How long you want the trading halt to last.

* The event you expect to happen that will end the trading halt.

* That you are not aware of any reason why the trading halt should not be
granted.

* Any other information necessary to inform the market about the trading
halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the
second day after the day on which it is granted. If a trading halt is requested
and granted and you are still unable to reply to this letter before the
commencement of trading, suspension from quotation would normally be imposed by
us from the commencement of trading if not previously requested by you. The
same applies if you have requested a trading halt because you are unable to
release information to the market, and are still unable to do so before the
commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours faithfully,

Julia Kagan

Adviser, Issuers (Melbourne)



Response:

22 August 2006


Ms Julia Kagan

Adviser, Issuer (Melbourne)

Australian Stock Exchange Limited

Level 3, Stock Exchange Centre

530 Collins Street

Melbourne Vic 3000


Dear Julia

Re: Phosphagenics Limited - Price Query

In response to your letter of 21 August the Company advises the following
responses:

1. No

2. Not applicable

3. As previously disclosed to ASX in the Company's 2005 Annual Report and
various announcements to ASX since that time, Phosphagenics has accelerated its
research programme, particularly its clinical (human) studies. In line with
this acceleration, Phosphagenics anticipates that the operating loss before
abnormal items and income tax for the half year ended 30 June 2006 will vary
materially (about $1.2 million greater) from the previous corresponding period.

4. No

5. Phosphagenics suggests that the following may provide some explanation for
the price changes and increase in volume in the securities of the Company:

A) Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

B) As previously reported to ASX on 24 July 2006 the Company commenced a
pivotal Phase I clinical trial its patented transdermal insulin delivery
platform. That announcement stated that the trial was expected to be completed
by the end of July with full analysis anticipated by September 2006. The
Company has no reason to expect that the receipt of the full analysis of the
trial and any consequence announcement to the ASX will not be within the
original time frame disclosed in the 24 July 2006 announcement. The Company is
also expecting a preliminary report from the principle investigator shortly and
will subsequently release details of this report.

6. We confirm the Company is in compliance with the Listing Rules, and in
particular Listing Rule 3.1.


Yours Faithfully

Phosphagenics Limited


Per Mourice Garbutt

Company Secretary

Getting better & better

stockdog, do you know anything about the following?

Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

I can't find it.

forest - no I don't , but isn't the ASX tedious - last year's accounts were barely readable for compliance guff and almost zilch info on the company. I always thought Ozzies were practical, easy-going folk, but ASX verges on the paranoid. Anything of real interest is ont he co's website, not in any formally required reporting.

I guess if the insti bought 3% or more PSG will have to announce this under AIM rules.

Think it more likely to be a strategic stake, rather than an opportunistic bete on soon to be released news, although no evidence to support this.

Another 3.5 years to run on my holding time frame, so plenty of time for one of thie products to really hit the market (apart from their vitE products already selling well).

sd

Thanks. Should get news soon on trials.

Not this soon!

Business Strategy
Financial News
Generics
Legal Actions
Patent Issues
Agency News
Electronic Marketing
Product Marketing News
Cardiovascular
Oncology
Pain & Inflammation
Central Nervous System
Infectious Disease
Contract Research Business
Drug Approvals
Drug Discovery
Drugs In Development
eR&D
Filed For Approval
Trial Results
Regulatory Actions
Warnings
FDA Policy
Investment Banking Healthcare
Medical/Professional


TRIAL RESULTS



Phosphagenics Successfully Delivers Insulin Across the Skin in Humans



No adverse reactions reported



Key points:


* TPM-02/Insulin applied as a gel delivered insulin through the skin and into the bloodstream

* TPM-02/Insulin significantly lowered blood glucose levels

* TPM-02/Insulin did not produce any adverse reactions

* TPM-02 carrier platform has now shown the ability to deliver large molecules (e.g. proteins) through the skin in humans

MELBOURNE, Australia, Aug. 24, 2006--Phosphagenics Limited ("Phosphagenics") (AIM:PSG; ASX: POH) announced today the interim results from its Phase I transdermal insulin clinical trial, demonstrating that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2.


>From one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time.


Dr William Hsu, co-investigator for this trial and clinician at the Joslin Diabetes Center of the Harvard Medical School, Boston, USA, said the trial results are evidence of the safety and tolerability of TPM-02/Insulin and demonstrate that this technology can deliver large molecules such as proteins through the skin.


"The primary objective was to confirm the safety and tolerability of TPM-02/Insulin, and this was achieved with no adverse reactions," Dr Hsu said.


"The trial also demonstrated the ability of TPM-02/Insulin to deliver insulin into the blood stream at levels high enough to produce significant effects. This is a very impressive result, given that it was administered as a single dose to healthy volunteers.


"This technology could eventually transform and expand the world's multi-billion dollar insulin market by providing a non-invasive and effective treatment for many of the world's 194 million diabetics, the majority of which are classified as Type 2," he said.


In the study, 20 healthy male volunteers, aged between 18 and 45, fasted overnight and then randomly received a single dose of TPM-02/Insulin or a placebo gel, applied directly onto the skin. Volunteers were then monitored for a period of 48 hours to assess the primary endpoint of safety.


Conducted at the Centre for Clinical Studies in Melbourne, Australia, and in accordance with ICH GCP standards and under the guidance and supervision of Professor Leon Bach, blood glucose and insulin levels, and the insulin biomarker C-peptide were all measured as secondary endpoints.


"To see TPM-02/Insulin produce a statistically significant and sustained effect on key markers, such as blood glucose concentration, insulin, and C-peptide is very encouraging and warrants significant future development," Dr Hsu said.


Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics, said that this was a milestone for Phosphagenics and allows it to now move rapidly into its next stage of development with TPM-02/Insulin.


"With this success we will now start exploring ways to apply this technology to other pharmaceutical products, as well as developing other routes of administration, such as oral and inhalation," Dr Ogru said.


Phosphagenics Managing Director, Harry Rosen added: "This result supports our recent focus on developing this novel patented technology. We expect this development to enhance international interest in Phosphagenics' technology as it is a key milestone in the delivery of large molecules effectively and safely through the skin

Shares in Phosphagenics jumped 2p to 15.5p after the company unveiled potentially very exciting results from one of its trials. The group said that the interim results from its Phase I transdermal insulin clinical trial demonstrated that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2. It said that from one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time

Great news - patience rewarded!

More to come, long term. A bit in the times today under the headline "smaller stock to watch"

Phosphagenics signs development deal with 'major cosmetics co'
LONDON (AFX) - Australian biotech group Phosphagenics Ltd said it has signed a development deal with what it described as a one of the world's largest cosmetics companies.

The unnamed 'major cosmetics company' will test the feasibility of using Phosphagenics' platform technologies to enhance the delivery of cosmetic compounds.

Phosphagenics has also recently signed development deals with food company Nestle Nutrition and through-the-skin drug delivery company ALZA Corp

sd
radiocast by MD on the following www.boardroomradio.com 30th aug